Header Logo

Connection

Heather Feigelson to Humans

This is a "connection" page, showing publications Heather Feigelson has written about Humans.
Connection Strength

1.838
  1. The Kaiser Permanente Research Bank Cancer Cohort: a collaborative resource to improve cancer care and survivorship. BMC Cancer. 2022 Feb 25; 22(1):209.
    View in: PubMed
    Score: 0.057
  2. A population-based survey to assess the association between cannabis and quality of life among colorectal cancer survivors. BMC Cancer. 2020 May 03; 20(1):373.
    View in: PubMed
    Score: 0.050
  3. Response to Comment on "Bariatric Surgery is Associated With Reduced Risk of Breast Cancer in Both Premenopausal and Postmenopausal Women". Ann Surg. 2020 02; 271(2):e19-e20.
    View in: PubMed
    Score: 0.049
  4. Financial burden and quality of life among early-onset colorectal cancer survivors: A qualitative analysis. Health Expect. 2019 10; 22(5):1050-1057.
    View in: PubMed
    Score: 0.047
  5. Melanoma incidence, recurrence, and mortality in an integrated healthcare system: A retrospective cohort study. Cancer Med. 2019 08; 8(9):4508-4516.
    View in: PubMed
    Score: 0.047
  6. Treatment patterns and survival differ between early-onset and late-onset colorectal cancer patients: the patient outcomes to advance learning network. Cancer Causes Control. 2019 Jul; 30(7):747-755.
    View in: PubMed
    Score: 0.047
  7. Health care improvement and survivorship priorities of colorectal cancer survivors: findings from the PORTAL colorectal cancer cohort survey. Support Care Cancer. 2019 Jan; 27(1):147-156.
    View in: PubMed
    Score: 0.044
  8. Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota. Br J Cancer. 2018 02 20; 118(4):471-479.
    View in: PubMed
    Score: 0.043
  9. Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivors. J Cancer Surviv. 2017 Jun; 11(3):393-400.
    View in: PubMed
    Score: 0.040
  10. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst. 2015 Aug; 107(8).
    View in: PubMed
    Score: 0.036
  11. Approaches to integrating germline and tumor genomic data in cancer research. Carcinogenesis. 2014 Oct; 35(10):2157-63.
    View in: PubMed
    Score: 0.034
  12. Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample. PLoS One. 2014; 9(5):e94977.
    View in: PubMed
    Score: 0.033
  13. Feasibility of self-collection of fecal specimens by randomly sampled women for health-related studies of the gut microbiome. BMC Res Notes. 2014 Apr 01; 7:204.
    View in: PubMed
    Score: 0.033
  14. Reply: To PMID 23490543. J Am Coll Surg. 2013 Nov; 217(5):960-2.
    View in: PubMed
    Score: 0.032
  15. Factors associated with the frequency of initial total mastectomy: results of a multi-institutional study. J Am Coll Surg. 2013 May; 216(5):966-75.
    View in: PubMed
    Score: 0.030
  16. Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories. BMC Res Notes. 2012 Apr 25; 5:196.
    View in: PubMed
    Score: 0.029
  17. Weight loss and postmenopausal breast cancer in a prospective cohort of overweight and obese US women. Cancer Causes Control. 2011 Apr; 22(4):573-9.
    View in: PubMed
    Score: 0.026
  18. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet. 2010 Oct 01; 19(19):3873-84.
    View in: PubMed
    Score: 0.025
  19. No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009 Sep; 18(9):2553-7.
    View in: PubMed
    Score: 0.024
  20. Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II. Breast Cancer Res. 2008; 10(4):R57.
    View in: PubMed
    Score: 0.022
  21. Successful genome-wide scan in paired blood and buccal samples. Cancer Epidemiol Biomarkers Prev. 2007 May; 16(5):1023-5.
    View in: PubMed
    Score: 0.020
  22. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer. 2006 Jul 01; 107(1):12-21.
    View in: PubMed
    Score: 0.019
  23. Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2006 Jun; 15(6):1236-7.
    View in: PubMed
    Score: 0.019
  24. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res. 2006 Feb 15; 66(4):2468-75.
    View in: PubMed
    Score: 0.019
  25. CYP17 genotype predicts serum hormone levels among pre-menopausal women. Hum Reprod. 2005 Aug; 20(8):2162-7.
    View in: PubMed
    Score: 0.018
  26. Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018. Breast Cancer Res Treat. 2024 Dec; 208(3):577-587.
    View in: PubMed
    Score: 0.017
  27. Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors. J Natl Cancer Inst. 2024 Aug 01; 116(8):1384-1394.
    View in: PubMed
    Score: 0.017
  28. No association between the progesterone receptor gene +331G/A polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):1084-5.
    View in: PubMed
    Score: 0.017
  29. Common colorectal cancer risk alleles contribute to the multiple colorectal adenoma phenotype, but do not influence colonic polyposis in FAP. Eur J Hum Genet. 2015 Feb; 23(2):260-3.
    View in: PubMed
    Score: 0.017
  30. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2004 Feb; 13(2):220-4.
    View in: PubMed
    Score: 0.016
  31. Improving Care for Marginalized Populations at Risk for Hereditary Cancer Syndromes: Innovations that Expanded Reach in the CHARM Study. Public Health Genomics. 2024; 27(1):16-22.
    View in: PubMed
    Score: 0.016
  32. Utilization of neoadjuvant chemotherapy varies in the treatment of women with invasive breast cancer. PLoS One. 2013; 8(12):e84535.
    View in: PubMed
    Score: 0.016
  33. Longitudinal adherence to breast cancer surveillance following cancer genetic testing in an integrated health care system. Breast Cancer Res Treat. 2023 Oct; 201(3):461-470.
    View in: PubMed
    Score: 0.016
  34. Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort. Breast Cancer Res. 2023 05 03; 25(1):50.
    View in: PubMed
    Score: 0.015
  35. Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. Genet Med. 2013 Dec; 15(12):933-40.
    View in: PubMed
    Score: 0.015
  36. Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2003 Feb; 12(2):161-4.
    View in: PubMed
    Score: 0.015
  37. Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study. Lancet Oncol. 2022 11; 23(11):1451-1464.
    View in: PubMed
    Score: 0.015
  38. Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis. 2002 Sep; 17(5):445-6; author reply 447-8.
    View in: PubMed
    Score: 0.015
  39. Risk-reducing surgery in unaffected individuals receiving cancer genetic testing in an integrated health care system. Cancer. 2022 Aug 15; 128(16):3090-3098.
    View in: PubMed
    Score: 0.014
  40. The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems. Cancer Causes Control. 2022 Jul; 33(7):1019-1023.
    View in: PubMed
    Score: 0.014
  41. Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016. Breast Cancer Res Treat. 2022 May; 193(1):203-216.
    View in: PubMed
    Score: 0.014
  42. An Examination of the Ethical and Legal Limits in Implementing "Traceback Testing" for Deceased Patients. J Law Med Ethics. 2022; 50(4):818-832.
    View in: PubMed
    Score: 0.014
  43. Alcohol consumption increases the risk of fatal breast cancer (United States). Cancer Causes Control. 2001 Dec; 12(10):895-902.
    View in: PubMed
    Score: 0.014
  44. Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study. BMJ Open. 2021 10 26; 11(10):e053397.
    View in: PubMed
    Score: 0.014
  45. Determinants of DNA yield and quality from buccal cell samples collected with mouthwash. Cancer Epidemiol Biomarkers Prev. 2001 Sep; 10(9):1005-8.
    View in: PubMed
    Score: 0.014
  46. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res. 2001 Jan 15; 61(2):785-9.
    View in: PubMed
    Score: 0.013
  47. Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. Breast Cancer Res. 2000; 2(4):277-82.
    View in: PubMed
    Score: 0.013
  48. Hormonal carcinogenesis. Carcinogenesis. 2000 Mar; 21(3):427-33.
    View in: PubMed
    Score: 0.012
  49. Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network. JCO Clin Cancer Inform. 2019 09; 3:1-10.
    View in: PubMed
    Score: 0.012
  50. Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res. 1999 Aug 15; 59(16):3908-10.
    View in: PubMed
    Score: 0.012
  51. Sex steroid hormones and genetic susceptibility to breast and prostate cancer. Drug Metab Rev. 1998 May; 30(2):421-34.
    View in: PubMed
    Score: 0.011
  52. Use of prenatal services by Hispanic women in San Diego County. A comparison of urban and rural settings. J Nurse Midwifery. 1998 Mar-Apr; 43(2):90-6.
    View in: PubMed
    Score: 0.011
  53. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res. 1998 Feb 15; 58(4):585-7.
    View in: PubMed
    Score: 0.011
  54. Re: Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst. 1997 Dec 03; 89(23):1810-2.
    View in: PubMed
    Score: 0.011
  55. Monitoring Lung Cancer Screening Use and Outcomes at Four Cancer Research Network Sites. Ann Am Thorac Soc. 2017 Dec; 14(12):1827-1835.
    View in: PubMed
    Score: 0.011
  56. Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis. Cancer Causes Control. 2018 01; 29(1):143-156.
    View in: PubMed
    Score: 0.011
  57. Association Between Weight Loss and the Risk of Cancer after Bariatric Surgery. Obesity (Silver Spring). 2017 11; 25 Suppl 2:S52-S57.
    View in: PubMed
    Score: 0.011
  58. Statin use and risk of multiple myeloma: An analysis from the cancer research network. Int J Cancer. 2017 08 01; 141(3):480-487.
    View in: PubMed
    Score: 0.010
  59. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 1997 Mar 15; 57(6):1063-5.
    View in: PubMed
    Score: 0.010
  60. Risk of Breast Cancer With Long-Term Use of Calcium Channel Blockers or Angiotensin-Converting Enzyme Inhibitors Among Older Women. Am J Epidemiol. 2017 02 15; 185(4):264-273.
    View in: PubMed
    Score: 0.010
  61. Estrogens and breast cancer. Carcinogenesis. 1996 Nov; 17(11):2279-84.
    View in: PubMed
    Score: 0.010
  62. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncol. 2017 02 09; 3(2):186-193.
    View in: PubMed
    Score: 0.010
  63. The Cancer Research Network: a platform for epidemiologic and health services research on cancer prevention, care, and outcomes in large, stable populations. Cancer Causes Control. 2016 11; 27(11):1315-1323.
    View in: PubMed
    Score: 0.010
  64. Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. Breast Cancer Res Treat. 2016 Feb; 155(3):531-40.
    View in: PubMed
    Score: 0.009
  65. Genetic susceptibility to cancer from exogenous and endogenous exposures. J Cell Biochem Suppl. 1996; 25:15-22.
    View in: PubMed
    Score: 0.009
  66. Socioeconomic Factors Affect Outcomes in Well-Differentiated Thyroid Cancer. Otolaryngol Head Neck Surg. 2016 Mar; 154(3):440-5.
    View in: PubMed
    Score: 0.009
  67. A simple screening method for peripheral arterial occlusive disease. J Vasc Surg. 1995 Jul; 22(1):122.
    View in: PubMed
    Score: 0.009
  68. Building Data Infrastructure to Evaluate and Improve Quality: PCORnet. J Oncol Pract. 2015 May; 11(3):204-6.
    View in: PubMed
    Score: 0.009
  69. Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases. Pharmacoepidemiol Drug Saf. 2015 Jul; 24(7):684-92.
    View in: PubMed
    Score: 0.009
  70. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin Endocrinol Metab. 2014 Dec; 99(12):4632-40.
    View in: PubMed
    Score: 0.009
  71. Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of noninvasive tests in a defined population. Am J Epidemiol. 1994 Sep 15; 140(6):526-34.
    View in: PubMed
    Score: 0.008
  72. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014 Dec 15; 23(24):6616-33.
    View in: PubMed
    Score: 0.008
  73. Developing a data infrastructure for a learning health system: the PORTAL network. J Am Med Inform Assoc. 2014 Jul-Aug; 21(4):596-601.
    View in: PubMed
    Score: 0.008
  74. The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr. 2013 Aug 01; 167(8):700-7.
    View in: PubMed
    Score: 0.008
  75. Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies. Genet Med. 2013 Sep; 15(9):721-8.
    View in: PubMed
    Score: 0.008
  76. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013 Apr; 45(4):392-8, 398e1-2.
    View in: PubMed
    Score: 0.008
  77. KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. Cancer Epidemiol Biomarkers Prev. 2013 Jan; 22(1):91-101.
    View in: PubMed
    Score: 0.007
  78. Utilization of HER2 genetic testing in a multi-institutional observational study. Am J Manag Care. 2012 Nov; 18(11):704-12.
    View in: PubMed
    Score: 0.007
  79. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012 Dec 15; 21(24):5373-84.
    View in: PubMed
    Score: 0.007
  80. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012 Sep 05; 104(17):1293-305.
    View in: PubMed
    Score: 0.007
  81. Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med. 2012 Jul; 14(7):633-42.
    View in: PubMed
    Score: 0.007
  82. Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010. JAMA. 2012 Jun 13; 307(22):2400-9.
    View in: PubMed
    Score: 0.007
  83. Improving quality of breast cancer surgery through development of a national breast cancer surgical outcomes (BRCASO) research database. BMC Cancer. 2012 Apr 03; 12:136.
    View in: PubMed
    Score: 0.007
  84. Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure. Cancer Epidemiol Biomarkers Prev. 2012 Apr; 21(4):673-80.
    View in: PubMed
    Score: 0.007
  85. Variability in reexcision following breast conservation surgery. JAMA. 2012 Feb 01; 307(5):467-75.
    View in: PubMed
    Score: 0.007
  86. Perception of direct-to-consumer genetic testing and direct-to-consumer advertising of genetic tests among members of a large managed care organization. J Genet Couns. 2012 Jun; 21(3):448-61.
    View in: PubMed
    Score: 0.007
  87. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011 Oct 30; 43(12):1210-4.
    View in: PubMed
    Score: 0.007
  88. Fine mapping of 14q24.1 breast cancer susceptibility locus. Hum Genet. 2012 Mar; 131(3):479-90.
    View in: PubMed
    Score: 0.007
  89. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011 Oct 01; 20(19):3867-75.
    View in: PubMed
    Score: 0.007
  90. Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Hum Mol Genet. 2011 Aug 15; 20(16):3322-9.
    View in: PubMed
    Score: 0.007
  91. Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum Mol Genet. 2011 Jul 15; 20(14):2869-78.
    View in: PubMed
    Score: 0.007
  92. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. Hum Genet. 2011 Jun; 129(6):675-85.
    View in: PubMed
    Score: 0.007
  93. Coronary disease and stroke in patients with large-vessel peripheral arterial disease. Drugs. 1991; 42 Suppl 5:16-21.
    View in: PubMed
    Score: 0.007
  94. Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). J Clin Endocrinol Metab. 2011 Feb; 96(2):E360-7.
    View in: PubMed
    Score: 0.007
  95. Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen. Int J Cancer. 2010 Dec 15; 127(12):2928-35.
    View in: PubMed
    Score: 0.007
  96. Menstrual cycle variability and the likelihood of achieving pregnancy. Rev Environ Health. 2010 Oct-Dec; 25(4):369-78.
    View in: PubMed
    Score: 0.006
  97. Leisure time spent sitting in relation to total mortality in a prospective cohort of US adults. Am J Epidemiol. 2010 Aug 15; 172(4):419-29.
    View in: PubMed
    Score: 0.006
  98. A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab. 2010 Sep; 95(9):E121-7.
    View in: PubMed
    Score: 0.006
  99. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010 Aug 01; 19(15):3089-101.
    View in: PubMed
    Score: 0.006
  100. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010 Mar 18; 362(11):986-93.
    View in: PubMed
    Score: 0.006
  101. Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Cancer Res. 2010 Mar 15; 70(6):2389-96.
    View in: PubMed
    Score: 0.006
  102. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis. 2010 Mar; 31(3):455-61.
    View in: PubMed
    Score: 0.006
  103. CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009 Oct; 18(10):2734-44.
    View in: PubMed
    Score: 0.006
  104. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet. 2009 Oct; 41(10):1055-7.
    View in: PubMed
    Score: 0.006
  105. Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). BMC Cancer. 2009 Jul 29; 9:257.
    View in: PubMed
    Score: 0.006
  106. Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). Hum Mol Genet. 2009 Oct 01; 18(19):3749-57.
    View in: PubMed
    Score: 0.006
  107. Family history of various cancers and pancreatic cancer mortality in a large cohort. Cancer Causes Control. 2009 Oct; 20(8):1261-9.
    View in: PubMed
    Score: 0.006
  108. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A. 2009 May 12; 106(19):7933-8.
    View in: PubMed
    Score: 0.006
  109. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet. 2009 May; 41(5):585-90.
    View in: PubMed
    Score: 0.006
  110. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet. 2009 May; 41(5):579-84.
    View in: PubMed
    Score: 0.006
  111. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer. 2009 Mar 01; 115(5):936-45.
    View in: PubMed
    Score: 0.006
  112. Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):297-305.
    View in: PubMed
    Score: 0.006
  113. The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer. 2008 Oct 15; 123(8):1877-82.
    View in: PubMed
    Score: 0.006
  114. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet. 2008 Sep; 40(9):1032-4; author reply 1035-6.
    View in: PubMed
    Score: 0.006
  115. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One. 2008 Jul 02; 3(7):e2578.
    View in: PubMed
    Score: 0.006
  116. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008 Mar; 40(3):310-5.
    View in: PubMed
    Score: 0.005
  117. Haplotypes of the estrogen receptor beta gene and breast cancer risk. Int J Cancer. 2008 Jan 15; 122(2):387-92.
    View in: PubMed
    Score: 0.005
  118. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):73-9.
    View in: PubMed
    Score: 0.005
  119. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2007 Oct; 16(10):1973-81.
    View in: PubMed
    Score: 0.005
  120. Cryopreservation of whole blood samples collected in the field for a large epidemiologic study. Cancer Epidemiol Biomarkers Prev. 2007 Oct; 16(10):2160-3.
    View in: PubMed
    Score: 0.005
  121. Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1140-7.
    View in: PubMed
    Score: 0.005
  122. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007 Jul; 39(7):870-4.
    View in: PubMed
    Score: 0.005
  123. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007 May; 39(5):645-9.
    View in: PubMed
    Score: 0.005
  124. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res. 2007 Apr 01; 67(7):2951-6.
    View in: PubMed
    Score: 0.005
  125. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 2007 Mar 01; 67(5):1893-7.
    View in: PubMed
    Score: 0.005
  126. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res. 2007; 9(1):R9.
    View in: PubMed
    Score: 0.005
  127. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006; 8(2):R22.
    View in: PubMed
    Score: 0.005
  128. Menstrual cycle characteristics: associations with fertility and spontaneous abortion. Epidemiology. 2006 Jan; 17(1):52-60.
    View in: PubMed
    Score: 0.005
  129. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Res. 2006; 8(5):R54.
    View in: PubMed
    Score: 0.005
  130. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer. 2005 12; 5(12):977-85.
    View in: PubMed
    Score: 0.005
  131. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2005 Dec; 14(12):2898-904.
    View in: PubMed
    Score: 0.005
  132. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet. 2005 Nov; 1(5):e68.
    View in: PubMed
    Score: 0.005
  133. A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk. Breast Cancer Res. 2005; 7(6):R1168-73.
    View in: PubMed
    Score: 0.005
  134. Risk factors for fatal breast cancer in African-American women and White women in a large US prospective cohort. Am J Epidemiol. 2005 Oct 15; 162(8):734-42.
    View in: PubMed
    Score: 0.005
  135. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2005 Jan; 14(1):261-4.
    View in: PubMed
    Score: 0.004
  136. Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev. 2002 Sep; 11(9):795-800.
    View in: PubMed
    Score: 0.004
  137. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer. 2002 May 01; 94(9):2490-501.
    View in: PubMed
    Score: 0.004
  138. Jewish ethnicity and prostate cancer mortality in two large US cohorts. Cancer Causes Control. 2002 Apr; 13(3):271-7.
    View in: PubMed
    Score: 0.004
  139. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer. 2002 Jan 15; 94(2):500-11.
    View in: PubMed
    Score: 0.004
  140. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res. 2001 Feb 01; 61(3):848-9.
    View in: PubMed
    Score: 0.003
  141. Declining cancer rates in the 1990s. J Clin Oncol. 2000 Jun; 18(11):2258-68.
    View in: PubMed
    Score: 0.003
  142. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 1998 Oct 15; 58(20):4497-504.
    View in: PubMed
    Score: 0.003
  143. A polymorphism in intron 6 of the CYP17 gene. Clin Genet. 1997 Jul; 52(1):68-9.
    View in: PubMed
    Score: 0.003
  144. T1 breast carcinoma in women 70 years of age and older may not require axillary lymph node dissection. Am J Surg. 1996 Nov; 172(5):487-9; discussion 489-90.
    View in: PubMed
    Score: 0.002
  145. IgE predicts future nonfatal myocardial infarction in men. J Clin Epidemiol. 1996 Feb; 49(2):203-9.
    View in: PubMed
    Score: 0.002
  146. The low HDL cholesterol/high triglyceride trait. Arterioscler Thromb. 1993 Apr; 13(4):495-504.
    View in: PubMed
    Score: 0.002
  147. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992 Feb 06; 326(6):381-6.
    View in: PubMed
    Score: 0.002

© 2024 Kaiser Permanente